Close Menu
Home › PGDx, PathGroup to Co-Develop Genomic Profiling Assay

PGDx, PathGroup to Co-Develop Genomic Profiling Assay

Jan 07, 2019

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced today that it has signed a co-development agreement with PathGroup for the PGDx Elio tissue-based complete assay.

As part of the agreement, the firms will partner on the necessary studies to support and secure US regulatory approval for the Elio tissue complete assay. PathGroup said it plans to be the first US laboratory to use the Elio panel.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13
Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
17
Featured Webinar

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
18
Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
25
Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

In Sequencing

  1. Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

  2. Biocept Shares Skyrocket on Commercial Launch of Lung Cancer Liquid Biopsy Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.